Successful PLA reimbursement announcement on 5 Decelmber (as above attached), then successful initiation of the CLIA waiver clinical trial today (19 December, as shown in below screenshot).
LDX kicking goals on a regular basis and making strides forward in terms of achieving their stated aims.
I am a particular fan of the following statement released in today's announcement:
"At the conclusion of the study, Lumos hopes to achieve a successful reclassification of FebriDx from moderate complexity to a CLIA-waived device. This would significantly increase its market reach in the US, with the total addressable market expanding from 18,000 to around 270,000 potential customer sites— a 15-fold increase — unlocking a potential market opportunity, valued at approximately US$1.7 billion annually."
Onwards and upwards.
=)
Add to My Watchlist
What is My Watchlist?
